New York Cancer and Blood Specialists(NYCBS) is dedicated to provide world-class, patient-centered, affordable care to patients with cancer and blood disorders in their own communities, close to family and friends. Our vision is a world free of cancer and blood disorders by contributing to the search for cures by offering cutting-edge clinical trials and personalized, state-of-the-art treatments that save and prolong lives. In support of these objectives NYCBS has created a centralized oncology biorepository in tandem with a longitudinal study to support translational research. This study establishes a biological sample bank and associated data reservoir from thousands of cancer patients, high risk populations, and survivors. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. Researchers will then use these samples and information to better understand how cancer affects the body over time in order to formulate new treatments. The information and samples provided will allow the testing of new therapies and aid in the development of new medical treatments.

Research and development of new diagnostics for earlier detection of, and new treatments for diseases require the use of human biological specimens (biospecimens). Through data and insight gained from the evaluation of these collected biospecimens, the aforementioned novel diagnostics and/or treatments can be developed or validated for a variety of diseases. Biospecimens collected under this protocol may be obtained from subjects with benign conditions, subjects who have been diagnosed with or suspected of having oncological diseases, infectious diseases, auto-immune diseases, endocrine disorders, as well as subjects from healthy normal donors.

The samples and data may be used for genetic research such as: RNA or DNA isolation and analysis, gene and protein expression, diagnostic device and biomarker research, tissue microarray development, laboratory tests and validation tests. The biospecimens may also be used for genome sequencing.

Inclusion Criteria:

1. Subjects must be at least 18 years of age
2. Subjects must be deemed competent by a qualified clinical study researcher to provide legally documented informed consent
3. Subjects may or may not have active disease at the time of enrollment
4. Biospecimens collected under this protocol may be obtained from subjects with benign conditions, subjects who have been diagnosed with or suspected of having oncological diseases, infectious diseases, auto-immune diseases, endocrine disorders, as well as subjects from healthy normal donors.

Exclusion Criteria:

4) Subjects not meeting the inclusion criteria

Additional inclusion and exclusion criteria may exist, specific to individual project plans, for each collection falling under this protocol. These criteria may include genetic mutation status, progression of disease, and prior lines of therapy among others.

Subjects diagnosed with or suspected of having cancerous disease, or from healthy, normal donors with the goal of aiding in biomarker research, early detection of disease, and development of new devices or therapies.